The development of coronary stents represents a major step forward in the treatment of obstructive coronary artery disease since the introduction of percutaneous coronary intervention. The initial enthusiasm for bare metal stents was, however, tempered by a significant incidence of in-stent restenosis, the manifestation of excessive neointima hyperplasia within the stented vessel segment, ultim...

Current drug-eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug release, more research on the <span style="font-size: 12pt; color: #000000; font-style: normal; ...

Drug-eluting stents have revolutionised the treatment of coronary artery disease. These small medical devices have attracted much interest over the past decade from biologists, clinicians, engineers and mathematicians alike. This article provides a comprehensive review of the modelling of drug release from arterial stents and the subsequent drug transport through arterial tissue, and acts as a ...

BACKGROUND The drug-eluting stents have decreased the incidence of instent restenosis compared to bare metal stents. But, the incidence of late and very late stent thrombosis has increased with the drug-eluting stents. CASE PRESENTATION We are here, reporting three cases of incredibly late instent thrombosis, each one occurring after more than 50 months of drug-eluting stent placement. CONC...

In-stent restenosis remains a significant problem associated with bare metal stents. This drawback has prompted research into improving stent design and the development of novel coatings, including drug-eluting stents. A number of drug-eluting stents are currently on the market; however, the success rate of these stents in complex situations has been found to be quite low. Thus, there remains p...

The efficacy of drug-eluting stents measured as the late loss, percentage neointimal volume, restenosis, target lesion revascularization and major cardiac events is significantly better than that of bare metal stents. The incidence of thrombosis and aneurysms is similar. Although there is a slight increase in late apposition, this is not followed by an increase in cardiac events. Despite the ar...

BACKGROUND The value of drug-eluting stents in preventing cardiovascular events has not been investigated in Mexico. OBJECTIVE To conduct a cost-effectiveness analysis of early and new-generation drug-eluting stents from the perspective of a healthcare provider. METHODS We conducted a cost-effectiveness analysis of early and new-generation drug-eluting stents in patients with ischemic cardi...

STUDY QUESTION What is the most safe and effective interventional treatment for coronary in-stent restenosis? METHODS In a hierarchical Bayesian network meta-analysis, PubMed, Embase, Scopus, Cochrane Library, Web of Science, ScienceDirect, and major scientific websites were screened up to 10 August 2015. Randomised controlled trials of patients with any type of coronary in-stent restenosis (...